Ajinomoto Cambrooke, Inc.
Manoj Nair, MBA, has a diverse and extensive work experience. Manoj served as the Director of Product Development at Ajinomoto Cambrooke, Inc. since December 2017. Prior to that, they worked at HP Hood LLC from 2014 to 2017, where they held the position of Manager ESL / Aseptic Technology. From 2007 to 2014, they held various roles at HP Hood LLC, including R&D Manager for Fluid Products and R&D Section Leader for Licensed and Food Service Products. Before joining HP Hood LLC, Manoj worked at Sartori Company from 2000 to 2007, serving as a Product Development Manager and Food Technologist. Earlier in their career, they were a Graduate Research Assistant at South Dakota State University from 1998 to 1999. Manoj also held positions at Vidya Dairy and Sumul Dairy, where they gained experience as a Shift Officer and Production Supervisor, respectively. Overall, Manoj has a strong background in product development, research, and leadership in the food industry.
Manoj Nair, MBA, has a diverse educational background that includes a master's degree in Business Administration from the Questrom School of Business at Boston University. Manoj completed this program from 2014 to 2015.
Prior to earning their MBA, Manoj pursued a master's degree in Dairy Science at South Dakota State University from 1998 to 1999. Manoj also holds a bachelor's degree in Dairy Science from Anand Agricultural University in Anand, which they obtained from 1989 to 1994.
In addition to their formal education, Manoj Nair has obtained a certification in Project Management: Planning, Scheduling & Control from the University of Wisconsin - Madison, School of Business in Madison, WI. The specific month and year of obtaining this certification are not provided.
This person is not in any teams
Ajinomoto Cambrooke, Inc.
Ajinomoto Cambrooke, Inc. formerly Cambrooke Therapeutics, Inc. (expansion of Cambrooke Foods) was founded in 2000 by Lynn and David Paolella, the parents of two children diagnosed with a rare disease called phenylketonuria (PKU). PKU is one of the few genetic diseases, which is managed almost entirely with nutritional intervention. The Paolellas’ goal in forming Cambrooke was simple - to develop improved nutritional therapeutic options for those with serious medical disorders. Today, Cambrooke produces medical formulas and foods for the management of a variety of medical conditions and we are continually innovating new nutritional options targeted at a wide array of diseases. Ajinomoto Cambrooke, Inc. - Leaders in Therapeutic Medical Nutrition. Cambrooke was the first medical foods company to launch a natural intact protein for the dietary management of phenylketonuria called Glytactin™ (modified glycomacropeptide). Cambrooke collaborates with academia and industry partners to transform early phase development projects in therapeutic nutrition into viable commercial products. Cambrooke employs scientific experts in the development, manufacturing and commercialization of nutritional therapeutics for patients with rare diseases. Cambrooke’s products are supported by clinical evidence for the nutritional management of medical needs before they are selected for commercialization. Cambrooke believes that both large and small patient populations are important when it comes to complex nutritional requirements.